Regeneron: Data Shows REGN-COV2 Reduced Virus Levels, Need for Further Medical Attention
October 28 2020 - 6:26PM
Dow Jones News
By Stephen Nakrosis
Regeneron Pharmaceuticals on Wednesday said positive prospective
results from an ongoing Phase 2/3 trial of its REGN-COV2 Antibody
Cocktail in Covid-19 patients demonstrated the treatment
"significantly reduced virus levels and need for further medical
attention."
The company said the recent data, involving 524 patients from
the ongoing trial in a Covid-19 outpatient setting, showed
REGN-COV2 "met the primary and key secondary endpoints," adding
that it "significantly reduced viral load and patient medical
visits."
Regeneron said it shared the results with the U.S. Food and Drug
Administration, which is "reviewing an Emergency Use Authorization
submission for the REGN-COV2 low dose in adults with
mild-to-moderate Covid-19 who are at high risk for poor
outcomes."
George D. Yancopoulos, president and chief scientific officer of
Regeneron, said, "Today's analysis, involving more than 500
additional patients, prospectively confirms that REGN-COV2 can
indeed significantly reduce viral load and further shows that these
viral reductions are associated with a significant decrease in the
need for further medical attention," adding, "We continue to see
the strongest effects in patients who are most at risk for poor
outcomes due to high viral load, ineffective antibody immune
response at baseline, or pre-existing risk factors."
The company said "REGN-COV2 is a combination of two monoclonal
antibodies (REGN10933 and REGN10987) and was designed specifically
to block infectivity of SARS-CoV-2, the virus that causes
Covid-19."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 28, 2020 19:11 ET (23:11 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024